Evidence map›Paper›PMID 37025715›Full record

ReviewCureus2023

Real World and Public Health Perspectives of Intraoperative Radiotherapy in Early-Stage Breast Cancer: A Multidisciplinary Analysis Beyond the Statistical Facts.

Srinivasan Vijayakumar, Mary R Nittala, Vedanth Buddala, Paul Mobit, William N Duggar, Claus Chunli Yang, Seth T Lirette, Eswar Mundra, Hiba Z Ahmed, Scott M Berry and 5 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Srinivasan VijayakumarRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Mary R NittalaRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Vedanth BuddalaRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Paul MobitRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
William N DuggarRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Claus Chunli YangRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Seth T LiretteData Science, University of Mississippi, Jackson, USA.
Eswar MundraRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Hiba Z AhmedRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Scott M BerrySurgery, University of Mississippi Medical Center, Jackson, USA.
Barbara S CraftMedicine, University of Mississippi Medical Center, Jackson, USA.
William C WoodsRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Jeremy OttsRadiation Oncology, University of Mississippi Medical Center, Jackson, USA.
Asal RahimiRadiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA.
Thomas DobbsPopulation Health, University of Mississippi Medical Center, Jackson, USA.
Jackson Memorial Hospital · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI GOMEZ-SANCHEZ, CELSO ENRIQUE · 2016 to 2025
$38.2M
NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

Breast conservation therapy (BCT) (usually a lumpectomy plus radiotherapy (RT)) has become a standard alternative to radical mastectomy in early-stage breast cancers with equal, if not higher, survival rates. The established standard of the RT component of the BCT had been about six weeks of Monday through Friday external beam RT to the whole breast (WBRT). Recent clinical trials have shown that partial breast radiation therapy (PBRT) to the region surrounding the lumpectomy cavity with shorter courses can result in equal local control, survival, and slightly improved cosmetic outcomes. Intraoperative RT (IORT) wherein RT is administered at the time of operation for BCT to the lumpectomy cavity as a single-fraction RT is also considered PBRT. The advantage of IORT is that weeks of RT are avoided. However, the role of IORT as part of BCT has been controversial. The extreme views go from "I will not recommend to anyone" to "I can recommend to all early-stage favorable patients." These divergent views are due to difficulty in interpreting the clinical trial results. There are two modalities of delivering IORT, namely, the use of low-energy 50 kV beams or electron beams. There are several retrospective, prospective, and two randomized clinical trials comparing IORT versus WBRT. Yet, the opinions are divided. In this paper, we try to bring clarity and consensus from a highly broad-based multidisciplinary team approach. The multidisciplinary team included breast surgeons, radiation oncologists, medical physicists, biostatisticians, public health experts, nurse practitioners, and medical oncologists. We show that there is a need to more carefully interpret and differentiate the data based on electron versus low-dose X-ray modalities; the randomized study results have to be extremely carefully

Indexed as

accelerated partial breast irradiationbreast cancer carebreast conservation therapyearly-stage breast cancerintraoperative radiotherapy

Identifiers

PMID37025715
PMCPMC10072193
OpenAlexW4327916337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.